|
Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). |
|
|
Honoraria - Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grunenthal; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Grunenthal; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech; Sysmex |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech |
|
|
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech |
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst) |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst) |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Leadership - Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb |
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Research Funding - Bristol-Myers Squibb; Novartis; Roche |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis |
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Research Funding - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Research Funding - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Robopharma; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme |
|
|
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche |
Speakers' Bureau - Merck Sharp & Dohme; Novartis; Pfizer; Roche |
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda |
Research Funding - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Novartis |
|
|
No Relationships to Disclose |
|
Elena Borisovna Grigoryeva |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |